U.S. Marine and Shipping Stock News

Nebius Group (NasdaqGS:NBIS) agreed to acquire Tavily, a real time agentic search company, to deepen its AI platform. The deal adds Tavily’s agent focused search technology and team to Nebius’s AI cloud stack. The acquisition is aimed at expanding integrated AI agent search capabilities for enterprise and developer customers. Nebius Group runs an AI focused cloud platform, so pulling Tavily’s real time agentic search into its stack fits closely with its core business. As more AI workloads...

In recent days, Marvell Technology filed two employee stock ownership plan-related shelf registrations to offer about US$333.80 million of common stock, totaling 4,373,572 shares, while also reporting past record quarterly revenue powered by AI-focused data center demand and its role in Amazon’s custom Trainium processors. These equity plan filings are small relative to Marvell’s AI infrastructure ambitions, where deepening ties to hyperscalers like Amazon and acquisitions such as XConn and...

Why Albertsons’ new Celebrations platform and AI push matter for shareholders Albertsons Companies (ACI) is back on investor radars after rolling out Celebrations, a digital event planning hub embedded in its grocery apps that uses AI to personalize shopping and speed up checkout. The launch is part of a broader technology push across merchandising, labor and supply chain. It offers a fresh angle on how a traditional grocer might use digital tools to influence customer behavior and operating...

Keefe, Bruyette & Woods recently highlighted a potentially attractive setup for Core Scientific (CORZ) as the company shifts focus from bitcoin mining to high performance computing leasing, drawing attention ahead of its February 18, 2026 earnings report. See our latest analysis for Core Scientific. At a share price of $18.09, Core Scientific has seen a 12.01% 7 day share price return and a 19.33% 90 day share price return, while its 1 year total shareholder return of 49.63% points to...

Royalty Pharma FY 2025 Earnings Snapshot Royalty Pharma (RPRX) has reported another quarter of royalty driven earnings, with Q3 FY 2025 revenue of US$609.3 million and basic EPS of US$0.67, alongside trailing 12 month revenue of about US$2.3 billion and EPS of US$1.76. The company’s quarterly revenue has moved from US$537.3 million in Q2 FY 2024 to US$593.6 million in Q4 FY 2024 and then into the US$568.2 million to US$609.3 million range across the first three quarters of FY 2025. Over the...

NetApp, Inc. recently presented at the WEST Conference 2026 at the San Diego Convention Center, highlighting its enterprise data infrastructure capabilities. The company’s growing success in winning new contracts, supported by billings growth and stronger efficiency-driven profits, underlines its operational momentum and cash generation strength. We’ll now explore how NetApp’s contract wins and efficiency gains might influence its investment narrative and future business positioning. The...

Liberty Broadband (NasdaqGS:LBRD.K) reports record annual revenue for 2025. The company completes a major rights offering to raise new capital. Proceeds are earmarked for infrastructure expansion and acquisitions planned for 2026. Liberty Broadband, which holds broadband and cable focused assets, is stepping into 2026 with record 2025 revenue and fresh capital from a sizeable rights offering. For investors, this pairs a new financial milestone with a stated plan to put newly raised funds to...

What Alnylam’s latest earnings tell you Alnylam Pharmaceuticals (ALNY) just reported Q4 and full year 2025 results that moved from losses to profits, with revenue and earnings shifting sharply higher compared with the previous year. For Q4 2025, revenue came in at US$1,097.03 million versus US$593.17 million a year earlier, and net income was US$111.54 million after a net loss of US$83.76 million in the prior year period. On a per share basis for the quarter, basic earnings from continuing...

Equity LifeStyle Properties (ELS) has declared a first quarter 2026 dividend of $0.5425 per common share, equivalent to $2.17 on an annualized basis, with payment scheduled for April 10 to shareholders of record on March 27. See our latest analysis for Equity LifeStyle Properties. At a share price of US$65.95, Equity LifeStyle Properties has seen a 10.30% year to date share price return and a 21.11% total shareholder return over five years. The recent dividend update helps frame current...

Alkermes (NasdaqGS:ALKS) has received Irish High Court approval to acquire Avadel Pharmaceuticals. The company has closed on more than US$1.5b in new credit facilities, which appears linked to funding the transaction. These developments mark a significant step in reshaping Alkermes' portfolio and capital structure. Alkermes focuses on neuroscience and oncology medicines, so adding Avadel Pharmaceuticals could reshape the mix of assets and future product opportunities. For investors, the...

In recent commentary, Federal Signal Corp. (NYSE:FSS) was highlighted for delivering 12.3% annual revenue growth over the past five years and an expected 15.6% sales increase over the coming twelve months, reflecting expanding demand for its safety and environmental solutions. An interesting takeaway is how this acceleration in projected sales growth reinforces perceptions that Federal Signal is capturing more business from municipalities and industrial customers seeking upgraded...

Axon Enterprise (AXON) is approaching its February 24, 2026 earnings release, with investors watching how a projected near 20% EPS decline compares with revenue growth that is expected to exceed 30%. See our latest analysis for Axon Enterprise. At a share price of $434.45, Axon Enterprise has seen a 31.23% 1 month share price decline and a 22.89% year to date pullback, while its 3 year total shareholder return of 118.33% and 5 year total shareholder return of 143.55% show that longer term...

If you have been wondering whether Morningstar's share price now lines up with its underlying worth, this article is designed to walk you through that question clearly and calmly. The stock last closed at US$155.35, with returns showing a 13.9% decline over 7 days, 28.9% decline over 30 days, 26.2% decline year to date, 51.1% decline over 1 year, 33.8% decline over 3 years and 36.3% decline over 5 years. These moves have arrived alongside ongoing investor interest in how Morningstar's...

If you are wondering whether Palomar Holdings at US$131.64 is offering fair value or a stretched price, you are in the right place. The stock has returned 7.0% over the last week, 0.9% over the past month, is roughly flat year to date at a 0.1% decline, and has returns of 20.8% over 1 year, 150.7% over 3 years and 28.6% over 5 years. Recent coverage has focused on how Palomar fits into the broader US insurance sector and how investors are treating companies that specialise in underwriting...

Harley-Davidson (HOG) is back in focus after its Q4 2025 update, where a larger than expected loss, weaker 2026 outlook and potential credit rating downgrade from S&P put fresh pressure on the stock. See our latest analysis for Harley-Davidson. The weak Q4 2025 earnings, cautious 2026 outlook and S&P credit watch have fed into a clear shift in sentiment, with Harley-Davidson’s 90 day share price return of 17.05% and 1 year total shareholder return of 18.93% both firmly negative and pointing...

If you are wondering whether Western Midstream Partners at around US$42.45 is offering good value today, you are not alone. This article is here to unpack what that price really reflects. The unit price has moved by 3.3% over the last week, 2.6% over the past month, 6.9% year to date and 16.9% over the past year, with a very large 3 year return and a strong 5 year return of 284.2% that may be changing how investors view its risk and reward profile. Recent coverage has focused on Western...

Generac Holdings (GNRC) has attracted attention after a strong recent run, with the share price up 17.9% on the day and gains extending over the past week and month. See our latest analysis for Generac Holdings. The sharp 17.9% 1 day share price return adds to a run of strong momentum, with the 30 day share price return at 37.3% and the 1 year total shareholder return at 41.0%, even though the 5 year total shareholder return sits at a loss of 39.5%. If this move in Generac has you thinking...

Pacira BioSciences (NASDAQ:PCRX) has had a rough three months with its share price down 8.6%. It seems that the market...

In early February 2026, DRDGOLD drew fresh attention as its recent performance was highlighted alongside stronger results from other gold miners, reinforcing perceptions of improved business outcomes. The company’s inclusion among peers benefiting from a healthier gold mining backdrop has reinforced its position as a potentially resilient sector participant. We’ll now examine how DRDGOLD’s favorable positioning within a strengthening gold mining sector shapes the company’s investment...

Celanese Corporation recently declared a quarterly cash dividend of US$0.03 per share on its common stock, payable on March 10, 2026 to shareholders of record as of February 24, 2026, and earlier this week raised prices for acetic acid, vinyl acetate monomer and related derivatives in the Western Hemisphere. This combination of a modest cash return to shareholders and immediate pricing actions in key chemical products underscores management’s focus on margin protection amid cautious earnings...

JM Group (JMG) has put fresh numbers on the table for FY 2025, with second half revenue of HK$122.0 million and basic EPS of HK$0.39, while the trailing twelve months show revenue of HK$269.4 million and EPS of HK$1.17 backed by net income of HK$18.7 million. The company has seen revenue move from HK$92.1 million and EPS of HK$0.12 in 2H 2024 to HK$147.3 million and EPS of HK$0.78 in 1H 2025, before landing at the latest half year figures. Over the past year, earnings growth of 165.4% has...

If you are wondering whether Cognex is fairly priced or if there is still value left on the table, this article is designed to walk you through that question in a clear, practical way. Cognex shares last closed at US$43.03, with returns of 5.6% over 7 days, 9.1% over 30 days, 16.5% year to date and 10.6% over 1 year, set against longer term returns of a 21.9% decline over 3 years and a 49.1% decline over 5 years that some investors may still have in mind. Recent coverage around Cognex has...

Why Texas Roadhouse stock is on investors’ radar Texas Roadhouse (TXRH) has attracted fresh attention after recent share price moves, with the stock posting mixed short term returns alongside stronger performance over the past 3 years and 5 years. See our latest analysis for Texas Roadhouse. At a share price of US$183.37, Texas Roadhouse’s recent 30 day share price return of a 2.48% decline contrasts with its 90 day gain of 9.08% and a 5 year total shareholder return of 134.66%. This...

Vertex Pharmaceuticals (NasdaqGS:VRTX) has entered an exclusive license and collaboration with WuXi Biologics to develop a trispecific T-cell Engager for B-cell mediated autoimmune diseases. The agreement focuses on a novel immunotherapy approach that aims to redirect T cells toward B cells involved in autoimmune activity. The partnership expands Vertex's pipeline beyond cystic fibrosis and gene editing into autoimmune indications that can represent large treatment markets. For you as an...